Company Overview
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.08.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +202.57% |
| 6 Months: | -6.10% |
| 3 Months: | +27.39% |
| 1 Month: | -4.76% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)49.78 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALXO ALX Oncology Holdings Inc. PHARMA | 2.00 | -1.74 | $276.55M | 0.00% | - | -80.65% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 1.29M | 1.26M | 655.00K | 527.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | -4.19M | -3.03M | -5.24M | -10.79M | -9.81M | -14.21M | -16.30M | -24.58M | -24.75M | -33.79M | -36.68M | -32.20M | -36.78M | -53.27M | -37.76M | -41.52M | -32.57M | -31.82M | -26.65M | -22.53M | -18.97M | -18.03M |
| Net Income | -4.24M | -4.20M | -3.04M | -5.45M | -11.33M | -10.18M | -14.19M | -16.27M | -24.57M | -24.53M | -32.92M | -35.32M | -30.18M | -34.16M | -50.99M | -35.58M | -39.40M | -30.71M | -30.75M | -25.95M | -22.14M | -17.93M | -17.97M |
| Diluted EPS | - | - | - | - | - | - | - | -0.40 | -0.61 | -0.60 | -0.81 | -0.87 | -0.74 | -0.84 | -1.24 | -0.71 | -0.76 | -0.58 | -0.58 | -0.49 | -0.41 | -0.17 | -0.13 |
| R&D Expense | - | 3.63M | 2.21M | 3.83M | 7.66M | 5.33M | 9.85M | 11.21M | 18.21M | 17.07M | 26.75M | 29.38M | 24.76M | 29.48M | 45.77M | 31.72M | 34.65M | 26.47M | 23.89M | 18.02M | 17.44M | 13.61M | 13.14M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.07M | 4.80M | 1.18M | 0 | 0 | - | - | - |
| Operating Income | -13.68M | -19.18M | -43.66M | -83.56M | -127.44M | -170.28M | -142.47M | -104.02M |
| Net Income | -13.73M | -19.24M | -45.74M | -83.46M | -123.48M | -160.81M | -134.85M | -101.69M |
| Diluted EPS | - | - | -2.76 | -2.07 | -3.03 | -3.74 | -2.58 | -1.90 |
| R&D Expense | 11.27M | 16.31M | 28.96M | 60.17M | 98.40M | 141.79M | 116.37M | 77.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 10.68M | 436.05M | 380.18M | 306.49M | 242.55M | 147.78M | 59.05M |
| Total Equity | -38.41M | -51.78M | -70.64M | 429.85M | 363.05M | 263.46M | 189.71M | 113.62M | 25.98M |
| Cash & Equivalents | - | - | 9.02M | 434.22M | 363.67M | 48.82M | 22.41M | 17.57M | 16.37M |
| Long Term Debt | - | - | 5.42M | - | - | 9.39M | 9.64M | 9.47M | 4.53M |
| Total Liabilities | - | - | 10.95M | 6.21M | 17.13M | 43.02M | 52.84M | 34.16M | 33.06M |
| Current Liabilities | - | - | 4.98M | 6.20M | 15.29M | 28.32M | 36.00M | 18.50M | 24.55M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -13.19M | -14.25M | -38.29M | -68.10M | -89.22M | -130.36M | -121.91M | -84.14M |
| Investing Cash Flow | -653.00K | -353.00K | 610.00K | -4.92M | -235.42M | 44.66M | 86.26M | 82.59M |
| Financing Cash Flow | 1.00K | 15.36M | 462.88M | 2.47M | 9.86M | 59.29M | 30.82M | 362.00K |
| Capital Expenditure | -653.00K | -353.00K | -31.00K | -666.00K | -1.43M | -1.27M | -447.00K | -212.00K |
| Free Cash Flow | -13.84M | -14.60M | -38.32M | -68.77M | -90.65M | -131.64M | -122.36M | -84.35M |
| Share Buybacks | 6.00K | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | -662.0% | -400.0% | -3,694.0% | - | - | - | - | - |
| Net Margin % | -664.3% | -401.2% | -3,869.7% | - | - | - | - | - |
| ROE % | 26.5% | 27.2% | -10.6% | -23.0% | -46.9% | -84.8% | -118.7% | -391.4% |
| ROCE % | - | -337.0% | -10.2% | -22.9% | -45.8% | -82.4% | -110.2% | -301.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 9.41% | 13.01M | $22.12M |
| 2 | venBio Partners LLC | 9.32% | 12.88M | $21.90M |
| 3 | Blackrock Inc. | 5.35% | 7.40M | $12.58M |
| 4 | Redmile Group, LLC | 5.35% | 7.39M | $12.57M |
| 5 | Blackstone Inc | 4.77% | 6.59M | $11.21M |
| 6 | Driehaus Capital Management, LLC | 4.36% | 6.03M | $10.24M |
| 7 | SilverArc Capital Management, LLC | 4.15% | 5.74M | $9.77M |
| 8 | TCG Crossover Management, LLC | 4.09% | 5.66M | $9.61M |
| 9 | Vanguard Capital Management LLC | 3.60% | 4.97M | $8.45M |
| 10 | Vivo Capital, LLC | 2.30% | 3.18M | $5.41M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALXO
ALX Oncology to Present at Upcoming Investor Conferences in September
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend pa…
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Here is how ALX Oncology Holdings Inc. (ALXO) and Medpace (MEDP) have performed compared to their sector so far this year.
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer – – Presented encou…
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph.D., After More Than a Decade of Foundational Leadership SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE…
ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs
ALX Oncology (NASDAQ:ALXO) executives said the company is focused on advancing two clinical-stage oncology programs, with upcoming data readouts expected to shape potential later-stage development plans for its lead CD47 program, evorpacept…
ALX Oncology (ALXO) Q1 2026 Earnings Transcript
Most notably, we are very excited to share with you the data set that was presented yesterday in Munich at ESMO Breast 2026 from the analysis of our trial evaluating evorpacept and zanidatamab, which clearly showed again that CD47 expressio…
ALXO — Frequently Asked Questions
What is the current share price of ALX Oncology Holdings Inc. (ALXO)?
As of 2026-09-19 21:16 PDT, ALX Oncology Holdings Inc. (ALXO) trades at $2.00 on NasdaqGS. Its 52-week range is $0.64 to $2.60.
What is the market capitalisation of ALXO?
ALX Oncology Holdings Inc. (ALXO) has a market capitalisation of $276.55M on NasdaqGS.
What is the P/E ratio of ALXO?
ALXO trades at a trailing price-to-earnings (P/E) ratio of -1.74. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.87.
What is the return on equity (ROE) of ALXO?
ALXO has a return on equity (ROE) of -80.65%.
Is ALXO a good stock to buy?
This page provides a data-driven analysis of ALX Oncology Holdings Inc. (ALXO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.